Skip to content

Biopas is thrilled to announce an exclusive agreement with Proveca Ltd to commercialise Sialanar® throughout the Spanish speaking territories in Latin America, and thus further strengthening its leadership position in treatments of the Central Nervous System

Under the terms of the agreement, Biopas will have exclusive rights to distribute, market, and seek reimbursement for Sialanar® within its paediatric indication in Argentina, Chile, Ecuador, Peru, Panama, Costa Rica, Colombia and Mexico. It is estimated that approximately 19,000 children with neurodisabilities suffer today from sialorrhoea in this Latin American region.

Sialanar® (320 mcg/ml glycopyrronium, oral solution) received a European Paediatric Use Marketing Authorisation (PUMA) on 15th September 2016 for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. Sialanar® is being used to treat children across most countries in Europe and the UK.

Full product information on Sialanar® can be found here:®#product-information-section

Dr Simon Bryson, CEO and founder of Proveca Ltd, commented:

“We are delighted to announce this agreement with Biopas to make Sialanar available to children with neurodisabilities who suffer from sialorrhoea. As in many countries across the world there is a high unmet need to manage this condition and improve the quality of the lives of patients and their carers. We are looking forward to working with Biopas who can offer their first-class capabilities to support the launch of Sialanar® in the Latin American region. This is a significant agreement outside the EU for Sialanar as part of our commercialisation strategy to optimise access of our products across the world”

Pascal Forget, CEO and Co-Founder of Laboratoires Biopas

“This significant partnership will allow Biopas and Proveca Ltd to actively pursue their mission of providing highly innovative products to cover unmet medical needs for patients in the Latin American region. The partnership further strengthens and consolidates Biopas CNS portfolio and its robust and strategic regional leadership position, allowing Biopas to provide new treatment options not previously available in Latin America to paediatric patients.”

About Proveca Ltd

Proveca Ltd is a pharmaceutical company based in Europe specialising in the development and licensing of medicines to address the unmet medical needs of children. The team at Proveca are seeking to improve the lives of children, many of whom require long-term drug treatment for chronic conditions. Working with clinicians, parents, carers and children, Proveca are leading the way in providing licenced, clinically proven, medicines that are tailored to the specific needs of children.
For further information about Proveca Ltd, please visit

About Biopas Laboratories

Biopas is a leading and differentiated Latin American Pharmaceutical company, focused on in-licensing, marketing and selling cutting-edge specialty pharmaceutical products. Biopas offers the best-in-class capabilities in sales, marketing, medical, support functions and provides integral services to support the launch and development of products. All its functions operate in compliance with international standards and regulations. Biopas covers 20+ countries in LatAm through fully owned subsidiaries and is a trusted partner of reputable multinational pharmaceutical companies and have products in leading positions in CNS, Immunology, Rare Disease, Oncology and Dermatology.
For further information about Biopas Laboratories, please visit
Created March 2022

Choose location